vs

Side-by-side financial comparison of Five Point Holdings, LLC (FPH) and Pulmonx Corp (LUNG). Click either name above to swap in a different company.

Pulmonx Corp is the larger business by last-quarter revenue ($20.6M vs $13.6M, roughly 1.5× Five Point Holdings, LLC). Five Point Holdings, LLC runs the higher net margin — -16.4% vs -66.3%, a 49.9% gap on every dollar of revenue. On growth, Five Point Holdings, LLC posted the faster year-over-year revenue change (3.2% vs -8.7%). Over the past eight quarters, Pulmonx Corp's revenue compounded faster (-0.5% CAGR vs -48.5%).

Five Point Holdings, LLC is a leading U.S. real estate development company that focuses on planning and constructing large-scale master-planned mixed-use communities in high-demand markets across California. Its projects integrate residential housing, commercial office spaces, retail outlets, public amenities and recreational facilities to build vibrant, sustainable living and working environments for local populations.

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

FPH vs LUNG — Head-to-Head

Bigger by revenue
LUNG
LUNG
1.5× larger
LUNG
$20.6M
$13.6M
FPH
Growing faster (revenue YoY)
FPH
FPH
+11.9% gap
FPH
3.2%
-8.7%
LUNG
Higher net margin
FPH
FPH
49.9% more per $
FPH
-16.4%
-66.3%
LUNG
Faster 2-yr revenue CAGR
LUNG
LUNG
Annualised
LUNG
-0.5%
-48.5%
FPH

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
FPH
FPH
LUNG
LUNG
Revenue
$13.6M
$20.6M
Net Profit
$-2.2M
$-13.7M
Gross Margin
77.9%
Operating Margin
-43.5%
-40.9%
Net Margin
-16.4%
-66.3%
Revenue YoY
3.2%
-8.7%
Net Profit YoY
-109.6%
5.5%
EPS (diluted)
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FPH
FPH
LUNG
LUNG
Q1 26
$13.6M
$20.6M
Q4 25
$75.9M
$22.6M
Q3 25
$13.5M
$21.5M
Q2 25
$7.5M
$23.9M
Q1 25
$13.2M
$22.5M
Q4 24
$159.8M
$23.8M
Q3 24
$17.0M
$20.4M
Q2 24
$51.2M
$20.8M
Net Profit
FPH
FPH
LUNG
LUNG
Q1 26
$-2.2M
$-13.7M
Q4 25
$58.7M
$-10.4M
Q3 25
$21.1M
$-14.0M
Q2 25
$3.3M
$-15.2M
Q1 25
$23.3M
$-14.4M
Q4 24
$121.0M
$-13.2M
Q3 24
$4.8M
$-14.1M
Q2 24
$14.7M
$-15.3M
Gross Margin
FPH
FPH
LUNG
LUNG
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
FPH
FPH
LUNG
LUNG
Q1 26
-43.5%
-40.9%
Q4 25
89.0%
-43.8%
Q3 25
-66.9%
Q2 25
-62.0%
Q1 25
-64.6%
Q4 24
87.5%
-56.5%
Q3 24
83.6%
-69.3%
Q2 24
86.1%
-75.2%
Net Margin
FPH
FPH
LUNG
LUNG
Q1 26
-16.4%
-66.3%
Q4 25
77.3%
-46.1%
Q3 25
156.2%
-64.9%
Q2 25
44.4%
-63.6%
Q1 25
177.0%
-64.1%
Q4 24
75.7%
-55.4%
Q3 24
28.0%
-69.4%
Q2 24
28.8%
-73.7%
EPS (diluted)
FPH
FPH
LUNG
LUNG
Q1 26
$-0.33
Q4 25
$-0.25
Q3 25
$-0.34
Q2 25
$-0.38
Q1 25
$-0.36
Q4 24
$-0.33
Q3 24
$-0.36
Q2 24
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FPH
FPH
LUNG
LUNG
Cash + ST InvestmentsLiquidity on hand
$332.6M
$61.6M
Total DebtLower is stronger
$37.3M
Stockholders' EquityBook value
$2.3B
$45.8M
Total Assets
$3.2B
$120.0M
Debt / EquityLower = less leverage
0.82×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FPH
FPH
LUNG
LUNG
Q1 26
$332.6M
$61.6M
Q4 25
$425.5M
$69.8M
Q3 25
$351.1M
$76.5M
Q2 25
$456.6M
$75.5M
Q1 25
$528.3M
$74.6M
Q4 24
$430.9M
$70.9M
Q3 24
$224.5M
$63.3M
Q2 24
$217.4M
$63.5M
Total Debt
FPH
FPH
LUNG
LUNG
Q1 26
$37.3M
Q4 25
$37.1M
Q3 25
$37.1M
Q2 25
$37.1M
Q1 25
$37.2M
Q4 24
$37.2M
Q3 24
$37.2M
Q2 24
$37.2M
Stockholders' Equity
FPH
FPH
LUNG
LUNG
Q1 26
$2.3B
$45.8M
Q4 25
$2.3B
$54.1M
Q3 25
$2.3B
$60.0M
Q2 25
$2.2B
$69.1M
Q1 25
$2.2B
$77.7M
Q4 24
$2.2B
$85.8M
Q3 24
$2.0B
$93.9M
Q2 24
$2.0B
$101.2M
Total Assets
FPH
FPH
LUNG
LUNG
Q1 26
$3.2B
$120.0M
Q4 25
$3.2B
$129.3M
Q3 25
$3.2B
$138.3M
Q2 25
$3.2B
$147.2M
Q1 25
$3.2B
$150.7M
Q4 24
$3.1B
$162.8M
Q3 24
$2.9B
$167.4M
Q2 24
$2.9B
$172.6M
Debt / Equity
FPH
FPH
LUNG
LUNG
Q1 26
0.82×
Q4 25
0.69×
Q3 25
0.62×
Q2 25
0.54×
Q1 25
0.48×
Q4 24
0.43×
Q3 24
0.40×
Q2 24
0.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FPH
FPH
LUNG
LUNG
Operating Cash FlowLast quarter
$-44.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FPH
FPH
LUNG
LUNG
Q1 26
$-44.5M
Q4 25
$105.2M
$-7.1M
Q3 25
$40.4M
$-8.2M
Q2 25
$-71.6M
$-3.9M
Q1 25
$56.7M
$-13.2M
Q4 24
$116.0M
$-6.7M
Q3 24
$-18.0M
$-7.2M
Q2 24
$-23.2M
$-5.8M
Free Cash Flow
FPH
FPH
LUNG
LUNG
Q1 26
Q4 25
$105.0M
$-7.1M
Q3 25
$-8.3M
Q2 25
$-71.7M
$-4.0M
Q1 25
$56.7M
$-13.5M
Q4 24
$115.2M
$-6.8M
Q3 24
$-18.2M
$-7.7M
Q2 24
$-23.6M
$-6.2M
FCF Margin
FPH
FPH
LUNG
LUNG
Q1 26
Q4 25
138.4%
-31.4%
Q3 25
-38.4%
Q2 25
-959.3%
-16.6%
Q1 25
430.9%
-60.0%
Q4 24
72.1%
-28.8%
Q3 24
-106.9%
-37.6%
Q2 24
-46.1%
-30.0%
Capex Intensity
FPH
FPH
LUNG
LUNG
Q1 26
0.0%
Q4 25
0.3%
0.1%
Q3 25
0.0%
0.4%
Q2 25
0.8%
0.2%
Q1 25
0.3%
1.3%
Q4 24
0.5%
0.5%
Q3 24
1.3%
2.0%
Q2 24
0.7%
2.3%
Cash Conversion
FPH
FPH
LUNG
LUNG
Q1 26
Q4 25
1.79×
Q3 25
1.92×
Q2 25
-21.58×
Q1 25
2.44×
Q4 24
0.96×
Q3 24
-3.77×
Q2 24
-1.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons